1 Transcriptional heterogeneity of stemness phenotypes in the ovarian epithelium

2 Carter, LE.^{*1,2}, Cook, DP.^{*1,2}, McCloskey, CW.^{1,2}, Dang, T.¹, Collins, O.^{1,2}, Gamwell, LF.^{1,2},

3 Dempster, HA.^{1,2}, Vanderhyden, BC.^{1,2}

4 * Authors contributed equally

5 1. Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON,
6 Canada.

7 2. Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa,
8 ON, Canada.

9 Correspondence: Dr. Barbara Vanderhyden (bvanderhyden@ohri.ca)

10 Abstract

11 The ovarian surface epithelium (OSE) is a monolayer of epithelial cells covering the surface of
12 the ovary. During ovulation, the OSE is ruptured to allow release of the oocyte. This wound is
13 quickly repaired, but mechanisms of this repair are poorly understood. The contribution of
14 tissue-resident stem cells in the homeostasis of several epithelial tissues is widely accepted,
15 such as the intestinal epithelium, airway epithelium, and skin, but their involvement in OSE
16 maintenance is unclear. While putative stem cell populations in the OSE have been described,
17 how they are regulated is poorly defined. We show that traits associated with stem cells
18 (stemness) can be increased in OSE following exposure to the cytokine TGFβ1, overexpression
19 of the transcription factor *Snai1*, or deletion of *Brca1*. By assessing the gene expression profiles
20 of these populations, we show that stemness is often linked to mesenchymal-associated gene
21 expression and higher activation of ERK signalling, but it is not consistently dependent on their
22 activation. Expression profiles of these populations are extremely context specific, suggesting
23 that stemness may not correspond to a single, distinct population, but rather is a heterogenous
24 state that can possibly emerge from diverse environmental cues. Together, these findings
25 support that the OSE may not require distinct stem cell populations for long-term maintenance,
26 and may achieve this through transient dedifferentiation into a stem-like state.

27 Introduction

28 It is thought that stem cell populations are responsible for long-term maintenance of many adult
29 tissues. The characterization of stem cells associated with epithelial tissues has been an active
30 field of research for the past few decades. While several distinct stem cell populations have
31 been described, such as an LGR5+ population at the base of intestinal crypts¹, it is unclear if all
32 epithelial tissues are maintained by such a defined population. For example, it has been shown
33 that following stem cell depletion, differentiated airway epithelial cells can dedifferentiate and
34 become functional multipotent stem cells². It is also unclear if stem cells are necessarily
35 required to maintain epithelial tissues comprising a single cell type, as some baseline capacity
36 for proliferation could maintain the entire tissue. In the mesothelium, for example, there have

37 been reports of putative stem/progenitor cells for over two decades, but a well-defined stem cell
38 population has yet to be identified³.

39 The ovarian surface epithelium (OSE) is a promising tissue for studying stemness dynamics in
40 tissue maintenance. It is a monolayer of cells surrounding the ovary and, during each ovulation,
41 this tissue is ruptured to facilitate release of an oocyte. Afterwards, the OSE layer is rapidly
42 repaired⁴⁻⁷. Post-ovulatory wound repair is a poorly understood process despite ovulation being
43 a major non-hereditary risk factor for ovarian cancer.

44 Several putative OSE stem cell populations have been described, each defined by different cell
45 surface markers, including ALDH1A1, LGR5, LY6A (Sca-1), and more⁸⁻¹¹. The relationships
46 between populations described in these studies are still unclear. Further, it is unclear if these
47 populations are static or can emerge from differentiated OSE in response to ovarian dynamics.
48 We have previously shown that, like the mammary epithelium¹², induction of an
49 epithelial-to-mesenchymal transition (EMT) can transiently promote features of stem cells
50 (stemness) in differentiated OSE¹⁰. This is particularly relevant in the context of ovulation, as the
51 EMT is thought to be an important component of wound repair and the EMT-promoting cytokine
52 TGFB1 is present in follicular fluid, bathing adjacent OSE at ovulation^{10,13}. It is also secreted by
53 macrophages at the ovulatory wound and granulosa cells during follicular development^{14,15}.

54 Here, we further demonstrate that features of stemness can be enhanced in OSE cells. Profiling
55 gene expression of different populations with enhanced stemness, we demonstrate that some
56 features are relatively common, including EMT-associated expression patterns and higher
57 activity of ERK and NFkB signalling, but global expression profiles are widely variable and
58 stemness isn't exclusively dependent on these common features. Together, this work supports
59 that OSE tissue maintenance may not require a distinct stem cell population, but can emerge in
60 response to their environment. Further, different environmental conditions can give rise to
61 stem-like populations with different characteristics.

62 **Results**

63 **CD44 is a marker of EMT-associated stemness in OSE cells**

64 We have previously demonstrated that mouse OSE (mOSE) cells undergo an EMT and acquire
65 stem cell characteristics when exposed to TGFB1^{10,16}. To confirm these findings, we first
66 assessed the ability of TGFB1-treated mOSE cells to form self-renewing spheroids in
67 suspension culture. Treated cells formed over twice as many primary spheroids and, when
68 dissociated and cultured, were more efficient at successfully generating secondary spheroids,
69 confirming their ability to self-renew (**Fig. 1a**). Morphologically, mOSE spheres were large and
70 compact, regardless of whether they had been treated (**Fig. 1b**). To validate this enhanced
71 stemness in human cells, we performed these experiments on primary cultures of human OSE
72 (hOSE) cells. These cultures have a low proliferation rate *in vitro*, so to minimize the impact of
73 aggregation in our quantifications, we used methylcellulose-based suspension culture to
74 immobilize the cells. While these conditions, along with the slower proliferation, resulted in

75 smaller spheroids, TGFB1-treated hOSE cells formed 3 times as many spheroids as untreated
76 cells (**Fig 1c**).

77 To determine if this enhanced stemness is associated with the expression of previously reported
78 markers of OSE stem cells, we measured their expression throughout TGFB1 treatment in
79 mOSE cells. *Aldh1a1*, *Lgr5*, and *Nanog* did not increase throughout a week of treatment, and in
80 some cases even decreased over time (**Supplementary Fig. 1**). While this does not preclude
81 the possibility of these genes being valid markers of stem cell populations *in vivo*, these results
82 suggest that their regulation is independent from TGFB1-associated stemness.

83 To identify putative markers that are associated with this stemness, we assessed the expression
84 of a larger panel of markers from a commercial “Stem Cell Marker” qPCR array (**Fig. 1d**). This
85 identified several highly upregulated markers following 7 days of TGFB1 treatment, including
86 *Ncam1* (14-fold), *Cd44* (13-fold), and *Ascl2* (6-fold) (**Fig. 1d**). CD44 has long been associated
87 with stemness in mammary epithelial cells¹⁷ and more recently in the oviductal epithelium¹⁸. To
88 determine if CD44 can be used as a selective marker to enrich for stem cell characteristics, we
89 first validated that TGFB1 increases CD44 protein levels in mOSE cells (**Fig. 1e**;
90 **Supplementary Fig. 2**) and then sorted CD44^{high} cells from TGFB1-treated mOSE by
91 fluorescence-activated cell sorting (FACS). When placed in suspension culture, CD44^{high} cells
92 formed approximately 2.5 times as many spheroids (**Fig. 1f**).

93 **Transcriptional profiling of mOSE stemness**

94 We next sought to define a global profile of stemness, beyond a small number of markers.
95 Spheroids themselves have been demonstrated to be enriched with stem/progenitor
96 populations^{19–21}. Since untreated mOSE cultures are capable of sphere formation, albeit at a
97 lower frequency than TGFB1-treated mOSE cells, we reasoned that the transcriptional profile of
98 these spheroids may represent an intrinsic stemness program, independent from exogenous
99 factors. To compare this with TGFB1-induced stemness, we performed RNA-seq on mOSE cells
100 cultured as a monolayer or as spheroids, each with and without TGFB1 treatment.

101 Untreated mOSE cells cultured as spheroids exhibited striking differences from those cultured in
102 a monolayer, with 4950 differentially expressed genes between the conditions ($p < 0.05$,
103 absolute log fold change > 0.5) (**Fig. 2a; Supplemental Data 1**). Using an aggregate reference
104 of GO terms, KEGG pathways, Reactome pathways, and MSigDB Hallmark gene sets from the
105 Molecular Signatures Database (MSigDB)^{22,23}, we used gene set enrichment analysis (GSEA)
106 to identify biological features associated with these changes (**Fig. 2c; Supplemental Data 2**).
107 Spheroids were associated with decreased cell cycle, epithelial cell adhesion and, interestingly,
108 DNA repair. Along with these changes, spheroid culture activated expression of chemokine
109 signalling and wound repair programs. We also note that CD44, which we had used as a
110 selection marker for stemness in TGFB1-treated mOSE, was also expressed over 4-fold higher
111 in spheroids, whereas *Aldh1a1*, *Lgr5*, and *Ly6a* (*Sca-1*) were unchanged (**Fig. 2b**). We next
112 used the PROGENy algorithm to infer changes in signalling pathway activity across these
113 samples that may be contributing to these differences. Spheroids were associated with

114 increased activity of many signalling pathways, with the largest increases in Hypoxia, NFkB, and
115 MAPK signalling (**Fig 2d**). While GSEA results suggest several EMT-related changes, TGFB1
116 and WNT signalling are interestingly reduced, suggesting that this EMT program may be
117 activated through NFkB or ERK (**Fig 2d**).

118 While TGFB1 signalling was decreased in untreated spheroids, exogenous TGFB1 treatment
119 enhanced stemness, increasing the proportion of cells capable of forming self-renewing
120 spheroids. While these results are seemingly contradictory, week-long exposure to exogenous
121 TGFB1 may activate similar expression programs through secondary effects or signalling
122 crosstalk²⁴. We next assessed expression changes associated with TGFB1 exposure.
123 Week-long treatment of monolayer cultures resulted in 1508 differentially expressed genes ($p <$
124 0.05, absolute log fold change > 0.5) (**Fig. 3a; Supplemental Data 3**). This involved the
125 activation of EMT-associated gene sets as expected, as well as a reduction in oxidative
126 phosphorylation (**Fig. 3b; Supplemental Data 4**). While TGFB1 signalling was the only pathway
127 inferred to have significantly altered activity, the estimated activity of EGFR and MAPK was
128 higher in TGFB1-treated cells ($p = 0.1$ and 0.06 , respectively) (**Fig. 3c**). Consistent with this, the
129 GO term “ERK1 and ERK2 signalling cascade” was significantly enriched in upregulated genes
130 following TGFB1 treatment (**Fig. 3b**).

131 This suggests that TGFB1 treatment initiates sequential or parallel signals similar to those
132 present in spheroids. Consistent with this, untreated spheroids and TGFB1-treated mOSE
133 monolayers have a significant overlap in expression changes relative to untreated mOSE cells
134 cultured as a monolayer, sharing 270 upregulated genes and 293 downregulated genes (Fisher
135 exact $p = 3.0\text{e-}66$ and $2.8\text{e-}117$, respectively) (**Fig. 3d**). Conserved upregulated genes were
136 strongly enriched for EMT-associated genes, NFkB signalling, and angiogenesis (**Fig. 3e**).
137 Interestingly, very few gene sets were enriched in the conserved downregulated genes, with
138 only interferon response and substrate adhesion genes being enriched (**Fig. 3e**). Together, this
139 suggests that OSE stemness may involve higher activities of ERK and NFkB signalling and an
140 associated reduction in typical epithelial traits.

141 **Snail activation promotes a unique stemness program in mOSE cells**

142 Signalling pathways are highly pleiotropic and it is unclear if TGFB1-enhanced stemness is
143 activated from core EMT regulatory networks or alternative components regulated by TGFB1.
144 The EMT transcription factor *Snai1* (Snail) was upregulated in both TGFB1-treated mOSE cells
145 and spheroids, so to test if EMT activation without exogenous cytokines could promote
146 stemness, we derived mOSE cell lines with doxycycline-inducible Snail expression. Following
147 Snail induction, cells had a higher sphere forming capacity than cells without doxycycline
148 exposure, generating up to twice as many primary spheres and 3 times as many secondary
149 spheres when passaged (**Fig. 4a**).

150 We next assessed the expression of the putative stem cell markers *Cd44* and *Sca-1*, which are
151 both increased with TGFB1 treatment, and found that Snail induction had no effect on their
152 expression, suggesting that their validity as markers of stemness may be context specific. To

determine if Snail induction activates similar expression patterns to TGFB1-treated mOSE and spheroids, including higher ERK and NFkB activity, we performed RNA-seq on these cells with and without doxycycline. Snail-induced changes were more modest than with TGFB1 treatment or in spheroid culture, with only 85 upregulated and 44 downregulated genes ($p < 0.05$, absolute log fold change > 0.5 ; **Fig. 4b; Supplemental Data 5**). Interestingly, inferred pathway activity scores associated with EGFR, NFkB, MAPK, and TGFB1 were all unchanged following Snail induction (**Fig. 4c**). Further, no relevant gene sets associated with these pathways were enriched in the differentially expressed genes (**Fig. 4d**). The only gene sets associated with upregulated genes were largely related to cell morphology and extracellular matrix (ECM) remodelling (**Fig. 4d; Supplemental Data 6**). Consistent with TGFB1-treated mOSE and spheroids, the MSigDB Hallmark “Interferon Alpha Response” was the only gene set enriched in the downregulated genes following Snail induction (**Fig. 4d**). We note that of the 85 upregulated genes following Snail induction, 13 are shared with those commonly regulated in TGFB1 treatment and spheroids (**Fig. 4e**). These genes largely represent components of the ECM, including *Col18a1* and the metalloproteinases *Mmp9* and *Adamts4*. As the conditions share no consistently activated downstream signal that could be induced by ECM changes, these findings suggest that expression programs associated with stemness phenotypes are heterogeneous. Given frequent enrichment of gene sets associated with a mesenchymal phenotype, stemness may consistently involve higher levels of these traits, which can emerge from variable expression patterns²⁵.

BRCA1 loss promotes EMT-independent stemness in mOSE

Spheroids were associated with higher expression of many genes that were not affected by TGFB1. We noted that among these were several changes typically associated with ovarian cancer, including activation of the transcription factor *Pax8*, which is present in approximately 80% of ovarian tumors but not typically expressed in the OSE²⁶; activation of *Greb1*, which promotes ovarian cancer growth²⁷; and loss of *Brca1*, which, along with *Brca2*, is mutated in approximately 22% of high-grade serous ovarian tumours. Interestingly, loss of BRCA1 has been associated with promoting dedifferentiation and activation of EMT expression patterns in mammary epithelial cells²⁸.

As the association between BRCA1 loss and stemness in the OSE had not been assessed, we next derived a primary mOSE line from *Brca1*^{tm1Brn} mice harboring floxed *Brca1* alleles. To determine if BRCA1 loss enhanced stemness in these cells, we infected the cells with adenovirus containing either Cre recombinase (Ad-Cre) or GFP (Ad-GFP) as a control. Cre delivery, while not perfectly efficient, resulted in an approximately 60% reduction in BRCA1 levels across the population (**Supplemental Fig. 3**). When placed in suspension culture, cells with reduced BRCA1 formed over 5 times as many primary spheres and 3 times as many secondary spheres than control mOSE cells, suggesting that BRCA1 loss also enhances stemness in mOSE cells (**Fig. 5a**). These findings also support our previous finding that the expression of putative stemness markers may be context specific.

192 To assess if BRCA1 loss enhances stemness phenotypes *in vivo*, we crossed the *Brca1*^{tm1Brn}
 193 mice with *B6.129X1-Gt(ROSA)26Sor*^{tm1(EYFP)Cos/J} mice to generate a *Brca1*^{fl/fl}YFP mouse line,
 194 allowing us to track *Brca1*-null cells following exposure to Ad-Cre. These mice were injected
 195 intrabursally (IB) with Ad-Cre or PBS, and injected intraperitoneally (IP) with bromodeoxyuridine
 196 (BrdU). Ovaries were collected after a 30 day chase period and assessed for retention of the
 197 BrdU label and activation of the YFP reporter. Ad-Cre injection IB in *Brca1*^{fl/fl}YFP mice showed
 198 successful activation of the YFP reporter, compared to the PBS injection (**Fig. 5b**). When
 199 combining the IB injections with an IP BrdU injection, Ad-Cre treatment increased the number of
 200 label-retaining OSE cells (**Fig. 5c,d**). This increased label retention further supports that BRCA1
 201 loss can expand or induce populations of stem-like cells in the OSE.

202 To determine if BRCA1 loss results in similar expression patterns to other conditions associated
 203 with stemness, we performed RNA-seq on mOSE cells isolated from these mice infected with
 204 Ad-Cre or Ad-GFP. BRCA1 loss resulted in a large shift in gene expression, with 1499
 205 significantly upregulated genes and 1881 downregulated ($p < 0.05$, absolute log fold change >
 206 0.5; **Fig. 6a; Supplemental Data 7**). In mammary epithelium, the induction of EMT through
 207 *Brca1* deletion was presumed to be due to loss of BRCA1-mediated repression on the promoter
 208 of the EMT transcription factor *Twist1*. In contrast, we found that *Twist1* was approximately
 209 8-fold lower in *Brca1*-null mOSE cells (**Fig. 6a**). There were also no EMT-associated gene sets
 210 enriched in upregulated genes. Rather, upregulated genes were largely enriched for gene sets
 211 associated with cell membrane transporters and downregulated genes were associated with cell
 212 cycle, oxidative phosphorylation, and DNA repair (**Fig. 6b; Supplemental Data 8**). *Brca1*
 213 deletion did not result in other features of stemness we observed in previous conditions,
 214 including activation of ERK and NFkB, and repression of interferon alpha response genes (**Fig.**
 215 **6c**). *Brca1*-null cells were associated with reduced PI3K signalling and higher levels of estrogen
 216 signalling (**Fig. 6c**). Estrogen has been linked to EMT and stemness in other cell types²⁹, but
 217 this is presumed to be through crosstalk, activating growth factor signalling pathways, which we
 218 do not see in *Brca1*-null OSE cells.

219 Comparing the expression profiles of each condition associated with stemness phenotypes in
 220 this study, we find minimal overlap in the specific genes activated or repressed in each (**Fig.**
 221 **6d**). Ranking genes by the number of conditions they are activated or repressed in, we found
 222 that *Adamts4* and *Pnmal2* are the only genes upregulated in all four conditions (**Fig. 6e**).
 223 *Adamts4* has been linked to stemness in uveal melanoma through modulating crosstalk
 224 between the cells and their adjacent ECM³⁰. While this may be relevant here, conserved
 225 downstream signals promoting stemness remain elusive. We note high frequency of
 226 EMT-associated changes, including activation of Snail, various collagens, and repression of
 227 cytokeratins (**Fig. 6e**). Notably, however, specific EMT transcription factors and putative OSE
 228 stemness markers (*Lgr5*, *Aldh1a1*, *Ly6a*, *Nanog*, and *Cd44*) are only activated in 1-2 conditions,
 229 and are even repressed in some conditions (**Fig. 6e**).

230 Discussion

Several studies have reported putative stem cell populations in the OSE, but the relationships between these populations are unclear. The ability of differentiated epithelial cells to dedifferentiate and fulfil functional roles of stem cells has now been observed in several tissues, suggesting that static stem cell populations may not be required to maintain all tissues. In this study, we have further explored the ability of OSE cells to acquire features of stemness and have demonstrated it can be promoted by a variety of conditions. It may be expected that a common gene expression program would underlie the stemness phenotype, but we demonstrate that expression profiles are context-specific.

While transcriptional responses were variable, several patterns were recurrent across multiple conditions. We observed that induction of an EMT with TGFB1 treatment or Snail overexpression could promote stemness in OSE, but profiles of spheroids without cytokine treatment also showed EMT activation, which has also been seen with ovarian cancer cells³¹. As spheroid culture has been shown to enrich for cells with stem cell properties, these findings suggest that intrinsic stemness—independent of exogenous treatments—may be associated with a more mesenchymal phenotype. The relationship between the EMT and stemness is well documented^{12,32}, but there is growing evidence that stemness and EMT are not inextricably linked. For example, the EMT-promoted transcription factor PRRX1 suppresses stemness in breast cancer cells³³. Further, transcriptional dynamics of the EMT have been shown to be highly context-specific, which explains why it does not consistently promote stemness²⁵. Just as the EMT can occur without promoting stemness, we have shown that deletion of *Brca1* promotes stemness in OSE without activating any EMT-associated expression, including *Twist1* activation, which had been shown to drive stemness following *Brca1* deletion in mammary epithelial cells²⁸. Instead, *Brca1* loss caused many changes in cell membrane transport and metabolic genes. While the mechanism of induced stemness following *Brca1* loss is unclear, this provides strong evidence that stemness is not dependent on a mesenchymal expression profile and is perhaps as context-specific as the EMT response²⁵.

Several alterations in signalling pathway activity were also common across conditions. TGFB1 treatment and spheroids were associated with higher levels of ERK activity, which have both been linked to stemness in epithelial³⁴ and carcinoma cells³⁵. In EGF-free media, paracrine/autocrine signalling is established, maintaining ERK activity in stem cell populations of intestinal organoids³⁵. While these mechanisms may contribute to stemness in OSE spheroids or those treated with TGFB1, increased ERK activity was not enhanced following Snail overexpression or *Brca1* loss. Similarly, a gene set comprising interferon alpha response genes was downregulated following spheroid culture, TGFB1 treatment, and Snail overexpression. While it is unlikely that interferon alpha itself was present, it is possible that various signalling pathways may affect common target genes. Consistent with this, disruption of type 1 interferon signalling promotes stemness in breast cancer cells³⁶. None of these patterns, however, are consistent across all conditions, further supporting that mechanisms promoting stemness may vary considerably depending on environmental conditions (eg. ovulatory wound repair, tissue expansion during folliculogenesis, natural cell turnover).

271 While we have relied heavily on *in vitro* models here, this has enabled us to explore the ability of
272 OSE cells to acquire stemness following various experimental perturbations. This suggests that
273 differentiated epithelial cells may be capable of self-regulating tissue maintenance in response
274 to environmental cues, such as tissue damage. The expression profiles of this emergent
275 stemness may be variable, depending on the specific properties of the cells' microenvironment.
276 This model is particularly interesting because it is a stark contrast to how stem cells and
277 differentiation hierarchies have been viewed for the last several decades. The OSE is a
278 promising tissue to explore this further as it undergoes regular rupture and repair throughout
279 reproductive cycles, and is a simple tissue comprising a single cell type, which may be the most
280 likely to exhibit this behavior. Designing strategies to monitor stemness dynamics *in vivo* will be
281 critical to understand these behaviours in a normal physiological context.

282 **Methods**

283 **OSE cell isolation and culture**

284 The isolation and culture of mOSE cells was done as previously described¹⁰, in accordance with
285 the guidelines of the Canadian Council on Animal Care and under a protocol approved by the
286 University of Ottawa Animal Care Committee. Briefly, ovaries from randomly cycling female mice
287 (FVB/N, 6 weeks old) were collected and incubated in 0.25% Trypsin/PBS (Invitrogen) (37 °C,
288 5% CO₂, 30 min) to facilitate OSE removal. mOSE cells were isolated by centrifugation and
289 plated onto tissue culture plates (Corning) in mOSE media [α -Minimum Essential Medium
290 (Corning) supplemented with 4% FBS, 0.01 mg/mL insulin-transferrin-sodium-selenite solution
291 (ITSS; Roche), and 2 μ g/mL EGF (R&D Systems)]. hOSE cells were isolated and cultured as
292 previously described³⁷, with patient consent and under a protocol approved by the Ottawa
293 Health Science Network Research Ethics Board (Protocol #1999540). Briefly, ovaries from 5
294 different women were collected during surgery for reasons other than ovarian pathology. Using a
295 scalpel, hOSE cells were scraped from the ovarian surface and isolated by centrifugation in
296 hOSE media (Wisent Bioproducts) supplemented with 10% FBS. All mouse and human OSE
297 cells were passaged 2-3 times prior to experimental use and experiments were conducted with
298 cells of a passage number less than 25.

299 **Quantitative reverse transcription polymerase chain reaction (RT-PCR)**

300 The RNeasy Mini Kit (Qiagen) was used to extract RNA and the OneStep RT-PCR Kit (Qiagen)
301 was used to synthesize cDNA. Quantitative PCR was done using the ABI 7500 FAST qRT-PCR
302 machine (Applied Biosystems) using the Taqman gene expression (Life Technologies) and
303 SsoFast gene expression (Bio-rad) assays utilizing *Tbp* as an endogenous control. Primer
304 sequences are listed in Supplemental Table 1. RQ (relative quantity) was determined using the
305 cycling threshold for the gene of interest in control or untreated samples compared to the
306 cycling threshold in experimental samples, calculated using the Applied Biosystems 7500 FAST
307 v2.3 software.

308 **Western blot**

309 M-PER mammalian protein extraction reagent (GE Healthcare) was used to extract protein from
310 mOSE cells and run on NuPAGE 4-12% Bis-Tris gradient gels (Life Technologies).
311 Polyvinylidene difluoride membranes were used to transfer protein samples. Membranes were

312 blocked in 5% non-fat milk prior to antibody incubation. Antibody conditions are described in
313 Supplemental Table 2. Western blots were developed using Clarity™ Western ECL Substrate
314 (Bio-Rad) and the FluorChem FC2 imaging system (Alpha Innotech).

315 **Stem cell PCR array**

316 mOSE cells (1x10⁶ cells) were plated 24 hr prior to treatment with TGFB1 (10 ng/mL, R&D
317 Systems). RNA was collected 7 days post-TGFB1 treatment (RNAeasy Kit, Qiagen). cDNA
318 synthesis was performed using RT² First Strand Kit (Qiagen) and run on the RT² First Strand
319 Kit (Stem cell PCR array) (Qiagen). The array was run in triplicate (N=3) and analyzed using the
320 DataAnalysis Excel platform provided with the array kits.

321 **Snail-overexpressing mOSE cells**

322 mOSE cells stably expressing reverse tetracycline-controlled transactivator (rtTA) protein were
323 transduced with a lentiviral construct (pWPI) expressing the murine *Snai1* or *eGFP* under the
324 control of a doxycycline-inducible promoter and the hygromycin resistance gene under the
325 control of the *PGK* promoter. Transduced cells were selected for resistance to Hygromycin B.
326 200ng/mL of doxycycline was added to cultures for 4 days prior to all experiments
327 overexpressing Snail.

328 **Primary sphere-forming assays**

329 For free-floating spheres, mOSE cells were cultured in stem cell media [Dulbecco's Modified
330 Eagle's Medium: Nutrient Mixture F-12 (Sigma) supplemented with 1 X B27 supplement
331 (Invitrogen), 0.02 µg/mL EGF (R&D Systems), 0.04 µg/mL fibroblast growth factor (FGF; R&D
332 Systems), 4 µg/mL heparin (Sigma) and 0.01 mg/mL ITSS (Roche), and 2 µg/mL EGF (R&D
333 Systems)] at 5x10⁴ cells/mL in non-adherent 24-well culture plates (Corning) and incubated at
334 37 °C, 5% CO₂ for 14 days. Spheres were quantified using ImageJ using a pixel cutoff of >1000
335 pixels and a circularity limit of 0.5-1.0. For spheres cultured in methylcellulose, mOSE cells were
336 placed in a 1:1 mixture of methylcellulose and stem cell media at 5x10⁴ cells/mL in 24-well
337 culture plates (Corning), and incubated at 37 °C, 5% CO₂ for 28 days.
338 Methylcellulose-embedded spheres were quantified using ImageJ using a pixel cutoff of >500
339 pixels and a circularity limit of 0.5-1.0. For each experiment, a minimum of 3 replicates were
340 performed, each replicate was performed in three independent wells, spheres were counted in 4
341 fields per well, and the average count was reported.

342 **Secondary sphere-forming assay**

343 Primary free-floating mOSE spheres were collected and washed in PBS. Spheres were
344 dissociated by first incubating in trypsin/PBS (Invitrogen) at 37 °C for 10 min, then by passing
345 cells through a 25 gauge needle to obtain a single cell suspension. Single cell suspension was
346 verified using phase contrast microscopy. Cells were washed in PBS, counted using a
347 hemocytometer and plated in stem cell media at 5x10⁴ cells/mL. Cells were incubated in
348 non-adherent 24-well culture plates (Corning) at 37 °C, 5% CO₂ for 14 days. Spheres were
349 quantified using ImageJ using a pixel cutoff of >500 pixels and a circularity limit of 0.5-1.0.

350 ***Brca1* deletion in mOSE cells**

351 mOSE cells were isolated from homozygous *Brca1*^{tm1Bm} mice as described above and then
352 infected with Ad-Cre to achieve *Brca1* knockout. Ad-GFP was used as a control. Cells were
353 cultured for 1 week after infection prior to experimental use.

354 **BrdU pulse-chase**

355 *Brca1*^{tm1Bm} mice were bred to *B6.129X1-Gt(ROSA)26Sor*^{tm1(EYFP)Cos/J} mice to produce
356 *Brca1*^{fl/m}YFP mice. *Brca1*^{fl/m}YFP mice were injected IB with Ad-Cre (8x10⁷ PFU) or PBS on day 1
357 and injected IP with BrdU (0.25 mg daily) on days 7-10. Ovaries were collected on day 40 and
358 frozen in Optimal Cutting Temperature Compound.

359 **BrdU Immunofluorescence**

360 Frozen sections (5 µm) were fixed using formalin-vapor fixation overnight at -20 °C. Samples
361 were then hydrated in PBS and antigen retrieval performed using an antigen unmasking solution
362 (ph 6.0, Vector) in a steam chamber (Hamilton Beach). Slides were then washed in PBS and
363 blocked with 5% goat serum for 1 hr at room temperature. Primary antibodies against BRCA1
364 (1:200, H-300, rabbit), GFP (1:1000, ab13970, chicken), and BrdU (1:200, ab6326, rat) were
365 added and incubated overnight at 4 °C. Following a PBS wash, species-appropriate secondary
366 antibodies (1:250, Alexafluor 594 nm or 488 nm) were incubated for 1 hr at room temperature.
367 Slides underwent a final PBS wash and were mounted using Prolong Gold with DAPI
368 (ThermoFisher). Positive cells were counted manually.

369 **RNA-seq sample preparation**

370 For TGFB1 treatment of monolayer cultures, mOSE cells were plated 24hrs prior to the addition
371 of TGFB1 (10ng/mL, R&D Systems) and cells were collected after 4 days of treatment. For
372 inducible *Snail* expression and *Brca1* deletion, cells were plated for 24hr prior to the addition of
373 doxycycline (200 ng/mL, Sigma), and RNA was collected 4 days later. For sphere-forming
374 conditions, mOSE cells (1x10⁶) were first plated as monolayer cultures 24 hr prior to treatment
375 with TGFB1 (10 ng/mL, R&D Systems). Four days after the addition of TGFB1, mOSE cells
376 were then plated in free-floating sphere-forming conditions. Cells were maintained in
377 sphere-forming cultures for 2 weeks prior to RNA collection (RNAeasy Kit, Qiagen). TGFB1 was
378 replenished when placing mOSE cells in sphere-forming conditions.

379 **Library preparation and sequencing**

380 Total RNA was quantified using a NanoDrop Spectrophotometer ND-1000 (NanoDrop
381 Technologies, Inc.) and its integrity was assessed on a 2100 Bioanalyzer (Agilent Technologies).
382 Libraries were generated from 250 ng of total RNA as follows: mRNA enrichment was
383 performed using the NEBNext Poly(A) Magnetic Isolation Module (New England BioLabs).
384 cDNA synthesis was achieved with the NEBNext RNA First Strand Synthesis and NEBNext
385 Ultra Directional RNA Second Strand Synthesis Modules (New England BioLabs). The
386 remaining steps of library preparation were done using the NEBNext Ultra II DNA Library Prep
387 Kit for Illumina (New England BioLabs). Adapters and PCR primers were purchased from New
388 England BioLabs. Libraries were quantified using the Quant-iT™ PicoGreen® dsDNA Assay Kit
389 (Life Technologies) and the Kapa Illumina GA with Revised Primers-SYBR Fast Universal kit
390 (Kapa Biosystems). Average size fragment was determined using a LabChip GX (PerkinElmer)
391 instrument.

392 The libraries were normalized, denatured in 0.05 N NaOH and then diluted to 200 pM and
393 neutralized using HT1 buffer. ExAMP was added to the mix and the clustering was done on an
394 Illumina cBot and the flowcell was run on a HiSeq 4000 for 2x100 cycles (paired-end mode)
395 following the manufacturer's instructions. A phiX library was used as a control and mixed with

libraries at 1% level. The Illumina control software was HCS HD 3.4.0.38 and the real-time analysis program was RTA v. 2.7.7. The program bcl2fastq2 v2.18 was then used to demultiplex samples and generate fastq reads.

RNA-seq processing and differential expression

Transcript quantification for each sample was performed using Kallisto (v0.45.0)³⁸ with the GRCm38 transcriptome reference and the -b 50 bootstrap option. The R package Sleuth (v0.30.0)³⁹ was then used to construct general linear models for the log-transformed expression of each gene across experimental conditions. Wald's test was used to test for significant variables for each gene and the resultant p-values were adjusted to q-values using the Benjamini-Hochberg false discovery rate method. Significant genes were defined as genes with a q-value < 0.05. An effect size (beta coefficient of the regression model) cutoff of >0.5 or <-0.5 was also used for each data set.

Gene set enrichment analysis and pathway activity inference

GSEA was performed with the R package fgsea (v1.13.5)⁴⁰. GO terms, KEGG pathways, Reactome pathways, and Hallmark genesets were collected from the Molecular Signatures Database (MSigDB)^{22,23} and used to query differential expression results ranked by fold change. All gene sets discussed in the manuscript have a significant enrichment (Benjamini-Hochberg adjust p-value < 0.05). For pathway activity inference, we used the R package PROGENy (v1.9.6)⁴¹. Pathway activity was compared between experimental conditions using a simple linear model and p-values were adjusted using the Benjamini-Hochberg false detection rate method.

CD44 cell sorting

mOSE cells were treated with TGFβ1 (10 ng/mL, 2 days) prior to collecting cells for FACS. Cells (1x10⁷) were trypsinized and a single-cell suspension was made using a 40 μm cell strainer. Cells were labelled and sorted as previously described¹⁸. Briefly, cells were resuspended in a flow buffer (4% FBS in PBS) and incubated with anti-CD44 conjugated to allophycocyanin (1:5000; eBioscience, San Diego, CA) for 15 min at 4 °C. Unbound antibody was removed with washing buffer and the fraction of cells with surface protein labeled with CD44 antibody was determined using a MoFlo cell sorter (Dako Cytomation).

Data availability

Raw sequencing files have been deposited and are available along with processed transcript quantifications at GSE122875.

Acknowledgments

We thank the tissue donors for making this research possible. We also thank Dr. Ken Garson for generating mOSE cells with inducible *Snail* and inducible *GFP* expression. We wish to acknowledge the contribution of staff of the McGill University and Génome Québec Innovation Centre (Montreal, QC) for performing library preparation and sequencing associated with RNA-seq experiments. We also wish to acknowledge StemCore Laboratories (Ottawa, ON) for performing the FACS of CD44-positive mOSE cells. This work was supported by grants from the Canadian Institutes of Health Research and the National Science and Engineering Research Council (BCV). L.E.C. and L.F.G. were supported by Ontario Graduate Scholarships, D.P.C. by

437 a Frederick Banting and Charles Best Doctoral Award (CIHR), and C.W.M. by the Vanier
438 Canada Graduate Scholarship.

439 **Author Contributions**

440 L.E.C. and B.C.V. conceived the study. L.E.C., D.P.C., and B.C.V. interpreted results and wrote
441 the manuscript. L.E.C., L.F.G., O.C., H.A.D., and T.D. performed cell culture experiments, qPCR
442 analysis, and western blots. O.C. derived mOSE and hOSE cultures. C.W.M. performed mouse
443 experiments and immunofluorescence. D.P.C. and L.E.C. performed all computational analysis.

444 **Competing Interests**

445 The authors declare no competing interests.

446 **References**

- 447 1. Barker, N., van de Wetering, M. & Clevers, H. The intestinal stem cell. *Genes Dev.* **22**,
448 1856–1864 (2008).
- 449 2. Tata, P. R. *et al.* Dedifferentiation of committed epithelial cells into stem cells in vivo. *Nature*
450 **503**, 218–223 (2013).
- 451 3. Herrick, S. E. & Mutsaers, S. E. The potential of mesothelial cells in tissue engineering and
452 regenerative medicine applications. *Int. J. Artif. Organs* **30**, 527–540 (2007).
- 453 4. Singavarapu, R., Buchinsky, N., Cheon, D. J. & Orsulic, S. Whole ovary
454 immunohistochemistry for monitoring cell proliferation and ovulatory wound repair in the
455 mouse. *Reprod. Biol. Endocrinol.* **8**, 98 (2010).
- 456 5. Murdoch, W. J. Ovarian surface epithelium during ovulatory and anovulatory bovine estrous
457 cycles. *Anat. Rec.* **240**, 322–326 (1994).
- 458 6. Bjersing, L. & Cajander, S. Ovulation and the role of the ovarian surface epithelium.
459 *Experientia* **31**, 605–608 (1975).
- 460 7. Wright, J. W., Jurevic, L. & Stouffer, R. L. Dynamics of the primate ovarian surface
461 epithelium during the ovulatory menstrual cycle. *Hum. Reprod.* **26**, 1408–1421 (2011).
- 462 8. Ng, A. & Barker, N. Ovary and fimbrial stem cells: biology, niche and cancer origins. *Nat.*
463 *Rev. Mol. Cell Biol.* **16**, 625–638 (2015).

- 464 9. Auersperg, N. The stem-cell profile of ovarian surface epithelium is reproduced in the
465 oviductal fimbriae, with increased stem-cell marker density in distal parts of the fimbriae. *Int.*
466 *J. Gynecol. Pathol.* **32**, 444–453 (2013).
- 467 10. Gamwell, L. F., Collins, O. & Vanderhyden, B. C. The mouse ovarian surface epithelium
468 contains a population of LY6A (SCA-1) expressing progenitor cells that are regulated by
469 ovulation-associated factors. *Biol. Reprod.* **87**, 80 (2012).
- 470 11. Flesken-Nikitin, A. *et al.* Ovarian surface epithelium at the junction area contains a
471 cancer-prone stem cell niche. *Nature* **495**, 241–245 (2013).
- 472 12. Mani, S. A. *et al.* The epithelial-mesenchymal transition generates cells with properties of
473 stem cells. *Cell* **133**, 704–715 (2008).
- 474 13. Haensel, D. & Dai, X. Epithelial-to-mesenchymal transition in cutaneous wound healing:
475 Where we are and where we are heading. *Dev. Dyn.* **247**, 473–480 (2018).
- 476 14. Shaw, T. J. & Martin, P. Wound repair: a showcase for cell plasticity and migration. *Curr.*
477 *Opin. Cell Biol.* **42**, 29–37 (2016).
- 478 15. Knight, P. G. & Glister, C. TGF- β superfamily members and ovarian follicle development.
479 *Reproduction* vol. 132 191–206 (2006).
- 480 16. Carter, L. E. *et al.* COX2 is induced in the ovarian epithelium during ovulatory wound repair
481 and promotes cell survival†. *Biol. Reprod.* **101**, 961–974 (2019).
- 482 17. Hebbard, L. *et al.* CD44 expression and regulation during mammary gland development
483 and function. *J. Cell Sci.* **113 (Pt 14)**, 2619–2630 (2000).
- 484 18. Alwosaibai, K. *et al.* PAX2 maintains the differentiation of mouse oviductal epithelium and
485 inhibits the transition to a stem cell-like state. *Oncotarget* **8**, 76881–76897 (2017).
- 486 19. Herheliuk, T., Perepelytsina, O., Ugnivenko, A., Ostapchenko, L. & Sydorenko, M.
487 Investigation of multicellular tumor spheroids enriched for a cancer stem cell phenotype.

- 488 *Stem Cell Investig* **6**, 21 (2019).
- 489 20. Robertson, F. M. *et al.* Imaging and analysis of 3D tumor spheroids enriched for a cancer
490 stem cell phenotype. *J. Biomol. Screen.* **15**, 820–829 (2010).
- 491 21. Liao, M.-J. *et al.* Enrichment of a population of mammary gland cells that form
492 mammospheres and have in vivo repopulating activity. *Cancer Res.* **67**, 8131–8138 (2007).
- 493 22. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for
494 interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U. S. A.* **102**,
495 15545–15550 (2005).
- 496 23. Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set
497 collection. *Cell Syst* **1**, 417–425 (2015).
- 498 24. Luo, K. Signaling Cross Talk between TGF- β /Smad and Other Signaling Pathways. *Cold*
499 *Spring Harb. Perspect. Biol.* **9**, (2017).
- 500 25. Cook, D. P. & Vanderhyden, B. C. Context specificity of the EMT transcriptional response.
501 *Nat. Commun.* **11**, 1–9 (2020).
- 502 26. Tacha, D., Zhou, D. & Cheng, L. Expression of PAX8 in normal and neoplastic tissues: a
503 comprehensive immunohistochemical study. *Appl. Immunohistochem. Mol. Morphol.* **19**,
504 293–299 (2011).
- 505 27. Hodgkinson, K. *et al.* GREB1 is an estrogen receptor-regulated tumour promoter that is
506 frequently expressed in ovarian cancer. *Oncogene* **37**, 5873–5886 (2018).
- 507 28. Bai, F. *et al.* BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell
508 dedifferentiation during mammary and tumor development. *Cancer Res.* **74**, 6161–6172
509 (2014).
- 510 29. Di Zazzo, E. *et al.* Estrogen Receptors in Epithelial-Mesenchymal Transition of Prostate
511 Cancer. *Cancers* **11**, (2019).

- 512 30. Peris-Torres, C. *et al.* Extracellular Protease ADAMTS1 Is Required at Early Stages of
513 Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like
514 Features on Tumor Cells. *Cancers* **12**, (2020).
- 515 31. Rafehi, S. *et al.* TGF β signaling regulates epithelial-mesenchymal plasticity in ovarian
516 cancer ascites-derived spheroids. *Endocr. Relat. Cancer* **23**, 147–159 (2016).
- 517 32. Wilson, M. M., Weinberg, R. A., Lees, J. A. & Guen, V. J. Emerging Mechanisms by which
518 EMT Programs Control Stemness. *Trends Cancer Res.* (2020)
519 doi:10.1016/j.trecan.2020.03.011.
- 520 33. Ocaña, O. H. *et al.* Metastatic colonization requires the repression of the
521 epithelial-mesenchymal transition inducer Prrx1. *Cancer Cell* **22**, 709–724 (2012).
- 522 34. Beumer, J. & Clevers, H. Regulation and plasticity of intestinal stem cells during
523 homeostasis and regeneration. *Development* **143**, 3639–3649 (2016).
- 524 35. Brandt, R. *et al.* Cell type-dependent differential activation of ERK by oncogenic KRAS in
525 colon cancer and intestinal epithelium. *Nat. Commun.* **10**, 2919 (2019).
- 526 36. Castiello, L. *et al.* Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression
527 and Breast Cancer Stem Cells. *Cancer Immunol Res* **6**, 658–670 (2018).
- 528 37. Tonary, A. M., Macdonald, E. A., Faught, W., Senterman, M. K. & Vanderhyden, B. C. Lack
529 of expression of c-KIT in ovarian cancers is associated with poor prognosis. *Int J Cancer*
530 **89**, 242–250 (2000).
- 531 38. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq
532 quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).
- 533 39. Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential analysis of
534 RNA-seq incorporating quantification uncertainty. *Nat. Methods* **14**, 687–690 (2017).
- 535 40. Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis.

536 doi:10.1101/060012.

537 41. Schubert, M. *et al.* Perturbation-response genes reveal signaling footprints in cancer gene
538 expression. *Nat. Commun.* **9**, 20 (2018).

Figure 1. TGFβ1 promotes stemness in the OSE. **a.** Primary (left) and secondary (right) sphere-forming capacity of mOSE cells treated with TGFβ1 (10ng/mL). Data points represent the average number of spheres per 4 fields of view for each replicate. **b.** Phase contrast images of control and TGFβ1-treated spheroids. Scale bar=100μm. **c.** Primary sphere-forming capacity of human OSE treated with TGFβ1. **d.** Fold change values for a panel of putative stem cell markers in mOSE treated with TGFβ1 for 4 days. **e.** Relative protein quantifications of CD44 throughout a time course of TGFβ1 treatment in mOSE. Quantifications represent western blot pixel densitometry, normalized to B-actin and scaled to the mean intensity in untreated samples. A representative blot is included in Supplemental Figure 2b. **f.** Primary sphere-forming capacity of CD44⁻ and CD44⁺ mOSE cells. All boxplots show median value (horizontal black line),

549 estimated 25th and 75th percentiles, and whiskers represent 1.5 times the interquartile range.
550 Linear regression models were used for all statistical tests. * $p < 0.05$, ** $p < 0.01$.

Figure 2. Transcriptional profile of intrinsic mOSE stemness. **a.** Plot showing the distribution of differentially expressed genes in mOSE cells cultured as spheroids relative to a monolayer. Each point corresponds to a single gene. Selected genes related to stemness and/or the EMT are highlighted on the plot. Dashed lines correspond to significance criteria (absolute log fold change > 0.5, $p < 0.05$). **b.** Boxplots showing the expression values of putative mOSE stemness markers in mOSE cells cultured in a monolayer (Control) or as spheroids. Boxplots show median value (horizontal black line), estimated 25th and 75th percentiles, and whiskers represent 1.5 times the interquartile range. **c.** GSEA results for selected gene sets enriched in differentially expressed genes in mOSE spheroids. All gene sets are significantly enriched ($p < 0.05$) and normalized enrichment scores (NES) are shown. **d.** Inferred pathway activity in monolayer- and spheroid-cultured mOSE cells. Linear models were used for statistical testing for (b) and (d). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Figure 3. TGFβ1 promotes a distinct stemness phenotype. **a.** Plot showing the distribution of differentially expressed genes in monolayers of mOSE cells treated with TGFβ1 compared to untreated samples. Each point corresponds to a single gene. Selected genes related to stemness and/or the EMT are highlighted on the plot. Dashed lines correspond to significance criteria (absolute log fold change > 0.5, $p < 0.05$). **b.** GSEA results for selected gene sets enriched in differentially expressed genes following TGFβ1 treatment. All gene sets are significantly enriched ($p < 0.05$) and NES values are shown. **c.** Inferred pathway activity in untreated and TGFβ1-treated mOSE cells. P -values were computed from the t statistic of a linear regression model and were adjusted using the Benjamini-Hochberg false discovery rate (FDR) method. **d.** Plot comparing log fold-change values for spheroid-cultured and TGFβ1-treated mOSE. Dashed lines correspond to fold change cutoffs used to assess significance. **e.** Plots showing gene sets enriched in commonly up- or downregulated genes following both TGFβ1 treatment and spheroid culture. P -values were calculated using a Fisher exact test and were adjusted using the Benjamini-Hochberg FDR method.

Figure 4. Snail overexpression promotes stemness with minimal gene expression changes. **a.** Primary (left) and secondary (right) sphere forming capacity of mOSE cells overexpressing Snail. Data points represent the average number of spheres per 4 fields of view for each replicate. Boxplots show median value (horizontal black line), estimated 25th and 75th percentiles, and whiskers represent 1.5 times the interquartile range. **b.** Plot showing the distribution of differentially expressed genes following Snail overexpression. Each point corresponds to a single gene. Selected genes related to stemness and/or the EMT are highlighted on the plot. Dashed lines correspond to significance criteria (absolute log fold change > 0.5, $p < 0.05$). **c.** Inferred pathway activity in control and Snail-overexpressing mOSE cells. P -values were computed from the t statistic of a linear regression model and were adjusted using the Benjamini-Hochberg FDR method. No pathway is significantly different between conditions. **d.** GSEA results for selected gene sets enriched in differentially expressed genes following Snail overexpression. All gene sets are significantly enriched ($p < 0.05$) and NES values are shown. **e.** UpSet plot showing overlaps in differentially expressed genes between all conditions assessed ranked by the condition/overlap with the largest number of genes. The top chart shows the intersection size for the conditions highlighted in the middle grid. A single, unconnected point corresponds to genes unique to only that condition. The total number of differentially expressed genes in each condition is shown in the left chart.

Figure 5. *Brca1* deletion *in vivo* promotes increased label retention. **a.** Primary (left) and secondary (right) sphere forming capacity of mOSE cells following *Brca1* deletion by infection with Ad-Cre (*Brca1* KO). Cells infected with Ad-GFP were used as a control (Ctrl). Data points represent the average number of spheres per 4 fields of view for each replicate. **b.** Immunohistochemical staining of ovaries following intrabursal injection of PBS or Ad-Cre. Staining shows BRCA1 (red) and the YFP (green) reporter activated upon delivery of Cre recombinase. Nuclei are stained with DAPI (blue). Scale bar = 10µm. **c.** BrdU label retention (red) and YFP (green) signal in ovaries following intrabursal injection of either PBS or Ad-Cre. Scale bar = 100µm. **d.** Quantification of both BrdU+ cells in ovaries. All boxplots show median value (horizontal black line), estimated 25th and 75th percentiles, and whiskers represent 1.5 times the interquartile range.

Figure 6. Stemness phenotypes are transcriptionally diverse. **a.** Plot showing the distribution of differentially expressed genes following *Brca1* deletion by infection with Ad-Cre. Each point corresponds to a single gene. Selected genes related to stemness and/or the EMT are highlighted on the plot. Dashed lines correspond to significance criteria (absolute log fold change > 0.5 , $p < 0.05$). **b.** GSEA results for selected gene sets enriched in differentially expressed genes following *Brca1* deletion. All gene sets are significantly enriched ($p < 0.05$) and NES values are shown. **c.** Inferred pathway activity in control and Snail-overexpressing mOSE cells. *P*-values were computed from the *t* statistic of a linear regression model and were adjusted using the Benjamini-Hochberg FDR method. **d.** UpSet plot showing overlaps in differentially expressed genes between all conditions assessed ranked by the condition/overlap with the largest number of genes. **e.** Plots showing the number of assessed conditions that genes are either activated or repressed in. Selected genes are listed and putative stemness markers are underlined.

619 **Supplemental Figure 1. Expression of stemness markers through a time course of TGFB1**
620 **treatment.** qPCR results showing expression of stemness genes following varying lengths of
621 TGFB1 treatment. Boxplots show median value (horizontal black line), estimated 25th and 75th
622 percentiles, and whiskers represent 1.5 times the interquartile range. P -values were computed
623 from the t statistic of a linear regression model. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

624 **Supplemental Figure 2. CD44 increases following TGFB1 treatment.** **a.** qPCR results
625 showing expression of *Cd44* following varying periods of TGFB1 treatment. Boxplots show
626 median value (horizontal black line), estimated 25th and 75th percentiles, and whiskers
627 represent 1.5 times the interquartile range. *P*-values were computed from the *t* statistic of a
628 linear regression model. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$. **b.** Representative western blot of
629 CD44 and B-actin following following varying periods of TGFB1 treatment. Densitometric
630 quantifications of three blots are included in Figure 1e.

631 **Supplemental Figure 3. *Brca1* is efficiently deleted following the expression of Cre**
632 **recombinase. a.** Western blot of BRCA1 and B-actin of *Brca1^{fl/fl}* mOSE cells following infection
633 with either Ad-GFP (Ctrl) or Ad-Cre (*Brca1* KO). **b.** Boxplot of relative BRCA1 protein
634 quantifications from pixel densitometry. N=3 independent infections with Ad-GFP or Ad-Cre.
635 Boxplots show median value (horizontal black line), estimated 25th and 75th percentiles, and
636 whiskers represent 1.5 times the interquartile range. *P*-values were computed from the *t* statistic
637 of a linear regression model. ** *p*<0.01.